Covered recipient · General Payments record
CAROLYN L NOYES
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$1,633.58
- Reported across 85 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $326.97 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $61.16 | 3 |
| Amgen Inc. | $49.19 | 3 |
| Janssen Pharmaceuticals, Inc | $42.23 | 2 |
| Nevro Corp. | $31.50 | 1 |
| Acerta Pharma LLC | $31.44 | 2 |
| Exact Sciences Corporation | $24.89 | 1 |
| Novo Nordisk AS | $24.47 | 1 |
| ABBVIE INC. | $23.30 | 1 |
| SI-BONE, INC. | $21.55 | 1 |
| Astellas Pharma US Inc | $17.24 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $23.30 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107747981 | CMS |
| Amgen Inc. | $13.11 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115974940 | CMS |
| Amgen Inc. | $15.64 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117643231 | CMS |
| Amgen Inc. | $20.44 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117643233 | CMS |
| Astellas Pharma US Inc | $17.24 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139520563 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.08 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104281685 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.36 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105328970 | CMS |
| Exact Sciences Corporation | $24.89 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114497878 | CMS |
| Janssen Pharmaceuticals, Inc | $23.17 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078215039 | CMS |
| Janssen Pharmaceuticals, Inc | $19.06 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078215047 | CMS |
| Lilly USA, LLC | $23.83 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135543735 | CMS |
| Lilly USA, LLC | $24.10 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135585736 | CMS |
| Lilly USA, LLC | $13.23 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135578630 | CMS |
| Nevro Corp. | $31.50 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130774343 | CMS |
| Novo Nordisk Inc | $24.47 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100283690 | CMS |
| SI-BONE, INC. | $21.55 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120063823 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.